Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 13;10:1758835918778297. doi: 10.1177/1758835918778297

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2018

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 6. — (a) Efficacy of afatinib (-◊-), copanlisib (-□-) and a combination of afatinib and copanlisib (–Δ–) in the HER2-positive cell lines HCC1569, BT474, and HCC1954 stably expressing ERBB4-WT, V721I or S303F and (b) p-values for the difference in efficacy of the combination. Acid phosphatase toxicity assays were used to investigate the effect of a serial dilution of the drugs on these HER2-positive breast cancer cell lines over a 5-day period and the resulting dose-response curves were analyzed with CalcuSyn (Biosoft). Error bars are representative of standard deviations across triplicate experiments.

* = p < 0.05 relative to WT as calculated by the Student’s t test (two-tailed with equal variance). Afatinib:Copanlisib was tested at a 1:1 ratio (top conc 100nM:100nM).

HER, human epidermal growth factor-like receptor; WT, wildtype.